Results 151 to 160 of about 585,966 (213)

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia. [PDF]

Blood Adv
Heyman BM, Opat SS, Wahlin BE, Dimopoulos MC, Castillo JJ, Tedeschi A, Tam CS, Buske C, Owen RG, Leblond V, Trotman J, Barnes G, Chan WY, Schneider J, Allewelt H, Cohen A, Matous JV.   +16 more
europepmc   +1 more source

Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia. [PDF]

Haematologica
Medina-Gil D, Palomo L, Navarro V, Lázaro G, Martín-Mur B, Hernández C, Castells O, Sánchez B, Muñoz-Torres PM, Pagès C, Pujadas G, Esteve-Codina A, Cabirta A, Ferrà C, Alcoceba M, Terol MJ, Andreu R, Martí M, Abrisqueta P, Bosch F, Crespo M.   +20 more
europepmc   +1 more source

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis. [PDF]

Blood Adv
Shadman M, Brown JR, Mohseninejad L, Yang K, Burnett H, Neupane B, Williams R, Lamanna N, O'Brien SM, Tedeschi A, Tam CS.   +10 more
europepmc   +1 more source

Pharmacology and safety of TAS5315, a Bruton tyrosine kinase inhibitor, in healthy volunteers: First-in-human, randomized, ascending-dose studies. [PDF]

Br J Clin Pharmacol
Kumagai Y, Fujita T, Maeda M, Yamamoto A, Amano H.   +4 more
europepmc   +1 more source

Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B-Cell Malignancies. [PDF]

CPT Pharmacometrics Syst Pharmacol
Demin O, Ou Y, Kolesova G, Shchelokov D, Stepanov A, Musatova V, Sahasranaman S, Zhao Y, Liu X, Tang Z, Hanley WD.   +10 more
europepmc   +1 more source

Bruton tyrosine kinase inhibitor in non-IgM lymphoplasmacytic lymphoma: a case report and literature review. [PDF]

J Clin Exp Hematop
Ito K, Hirano K, Sekiguchi N.
europepmc   +1 more source

Is Bruton tyrosine kinase a potential target to treat mast cell neoplasms? Systemic mastocytosis associated with chronic lymphoid leukemia successfully treated with acalabrutinib monotherapy: a case report and review of the literature. [PDF]

Haematologica
Fazio M, Elena C, Ferrari J, Camilotto V, Stella S, Leotta D, Palumbo GA, Di Raimondo F, Romano A.   +8 more
europepmc   +1 more source

A matching-adjusted indirect comparison of survival outcomes with pirtobrutinib (BRUIN) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma previously treated with a covalent Bruton tyrosine kinase inhibitor. [PDF]

Br J Haematol
Heß G, Eyre TA, Jen MH, Zhang J, Goebel B, Abhyankar S, Dreyling M.   +6 more
europepmc   +1 more source

Incidence of pneumonia among bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis of clinical trials. [PDF]

Ann Hematol
Mahadevia H, Ponvilawan B, Shrestha A.
europepmc   +1 more source

Scedosporium Brain Abscess: A Rare and Fatal Drawback of Bruton Tyrosine Kinase Inhibitor Therapy. [PDF]

J Hematol
Dalmazzo M, Padrini M, Camerlo S, Rosati G, Busana TT, Nicoli P, Perotto F, Davicco L, Caironi P, De Gobbi M, Morotti A.   +10 more
europepmc   +1 more source